Literature DB >> 27422109

ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer.

William Small, John P Hayes, W Warren Suh, May Abdel-Wahab, Ross A Abrams, Nilofer Azad, Prajnan Das, Jadranka Dragovic, Karyn A Goodman, Salma K Jabbour, William E Jones, Andre A Konski, Albert C Koong, Rachit Kumar, Percy Lee, Timothy M Pawlik, Joseph M Herman.   

Abstract

The American College of Radiology Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. The panel reviewed the pertinent literature and voted on five variants to establish appropriate recommended treatment of borderline and unresectable pancreatic cancer. The guidelines reviewed the use of radiation, chemotherapy, and surgery. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.

Entities:  

Mesh:

Year:  2016        PMID: 27422109

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

Review 1.  Dual energy CT applications in pancreatic pathologies.

Authors:  Elizabeth George; Jeremy R Wortman; Urvi P Fulwadhva; Jennifer W Uyeda; Aaron D Sodickson
Journal:  Br J Radiol       Date:  2017-09-22       Impact factor: 3.039

2.  Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.

Authors:  Rosario Mazzola; Sergio Fersino; Dario Aiello; Fabiana Gregucci; Umberto Tebano; Stefanie Corradini; Gioacchino Di Paola; Massimo Cirillo; Luca Tondulli; Giacomo Ruffo; Ruggero Ruggieri; Filippo Alongi
Journal:  Strahlenther Onkol       Date:  2018-04-25       Impact factor: 3.621

3.  Intraoperative Radiation "Boost" to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report.

Authors:  Tarita O Thomas; William Small; Mark Fleming; Song Kang; Richard A Hoefer
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

4.  Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

Authors:  Christelle Bouchart; Jean-Luc Engelholm; Jean Closset; Julie Navez; Patrizia Loi; Yeter Gökburun; Thierry De Grez; Laura Mans; Alain Hendlisz; Maria Antonietta Bali; Pierre Eisendrath; Dirk Van Gestel; Matthieu Hein; Luigi Moretti; Jean-Luc Van Laethem
Journal:  Ther Adv Med Oncol       Date:  2021-10-19       Impact factor: 8.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.